August, 2024
August 2024
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Manni Mohyuddin: Long term follow up of elranatamab Phase 2 trial
Jul 28, 2024, 23:54

Manni Mohyuddin: Long term follow up of elranatamab Phase 2 trial

Manni Mohyuddin posted on X about recent paper by Michael H. Tomasson et al., titled Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study published on Wiley Online Library.

Authors: Michael H. TomassonShinsuke IidaRuben NiesvizkyMohamad MohtyNizar J. BahlisJoaquin Martinez-LopezGuenther KoehnePaula Rodriguez-OteroH. Miles PrinceAndrea ViqueiraEric LeipUmberto ConteSharon T. SullivanAlexander M. Lesokhin

Manni Mohyuddin: Long term follow up of elranatamab Phase 2 trial

“Long term follow up of elranatamab Phase 2 trial

n=123 97%
triple ref, 42% penta ref
Median PFS=17 mo
Median OS=24 mo
Many still in response at latest follow-up.”

Source: Manni Mohyuddin/X

Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.